Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
To determine whether celecoxib is superior to combined therapy with diclofenac and omeprazole
in the incidence of clinically significant upper and/or lower gastrointestinal (GI) events in
high GI risk subjects with osteoarthritis and/or rheumatoid arthritis.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.